Nadine M Brown

Summary

Affiliation: Cincinnati Children's Hospital Medical Center
Country: USA

Publications

  1. ncbi Impact of perinatal exposure to equol enantiomers on reproductive development in rodents
    Nadine M Brown
    Department of Pathology and Laboratory Medicine, Cincinnati Children s Hospital Medical Center, 3333 Burnet Ave, Cincinnati, OH 45229, USA
    Reprod Toxicol 32:33-42. 2011
  2. ncbi S-equol, a potent ligand for estrogen receptor beta, is the exclusive enantiomeric form of the soy isoflavone metabolite produced by human intestinal bacterial flora
    Kenneth D R Setchell
    Division of Pathology, Clinical Mass Spectrometry, Cincinnati Children s Hospital Medical Center, and the Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati 45229, OH, USA
    Am J Clin Nutr 81:1072-9. 2005
  3. ncbi Comparing the pharmacokinetics of daidzein and genistein with the use of 13C-labeled tracers in premenopausal women
    Kenneth D R Setchell
    Clinical Mass Spectrometry, Children's Hospital Medical Center, Cincinnati, OH, USA
    Am J Clin Nutr 77:411-9. 2003
  4. ncbi Soy isoflavone phase II metabolism differs between rodents and humans: implications for the effect on breast cancer risk
    Kenneth D R Setchell
    Division of Pathology and Laboratory Medicine, Cincinnati Children s Hospital Medical Center, OH 45229, USA
    Am J Clin Nutr 94:1284-94. 2011
  5. ncbi The pharmacokinetic behavior of the soy isoflavone metabolite S-(-)equol and its diastereoisomer R-(+)equol in healthy adults determined by using stable-isotope-labeled tracers
    Kenneth Dr Setchell
    Division of Pathology and Laboratory Medicine, Cincinnati Children s Hospital Medical Center, Cincinnati, OH 45229, USA
    Am J Clin Nutr 90:1029-37. 2009
  6. ncbi The chemopreventive action of equol enantiomers in a chemically induced animal model of breast cancer
    Nadine M Brown
    Division of Pathology and Laboratory Medicine, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio, OH 45229, USA
    Carcinogenesis 31:886-93. 2010
  7. ncbi Pharmacokinetics of a slow-release formulation of soybean isoflavones in healthy postmenopausal women
    Kenneth D R Setchell
    Division of Pathology, Department of Pediatrics, Cincinnati Children s Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA
    J Agric Food Chem 53:1938-44. 2005
  8. ncbi The clinical importance of the metabolite equol-a clue to the effectiveness of soy and its isoflavones
    Kenneth D R Setchell
    Clinical Mass Spectrometry, Department of Pediatrics, Cincinnati Children s Hospital Medical Center, OH 45229, USA
    J Nutr 132:3577-84. 2002
  9. ncbi Evidence for lack of absorption of soy isoflavone glycosides in humans, supporting the crucial role of intestinal metabolism for bioavailability
    Kenneth D R Setchell
    Division of Clinical Mass Spectrometry, Department of Pediatrics, Children s Hospital Medical Center, Cincinnati, OH 45229, USA
    Am J Clin Nutr 76:447-53. 2002

Detail Information

Publications9

  1. ncbi Impact of perinatal exposure to equol enantiomers on reproductive development in rodents
    Nadine M Brown
    Department of Pathology and Laboratory Medicine, Cincinnati Children s Hospital Medical Center, 3333 Burnet Ave, Cincinnati, OH 45229, USA
    Reprod Toxicol 32:33-42. 2011
    ..With R-(+)equol this stimulatory effect subsided after exposure was discontinued, but the effect of S-(-)equol was prolonged...
  2. ncbi S-equol, a potent ligand for estrogen receptor beta, is the exclusive enantiomeric form of the soy isoflavone metabolite produced by human intestinal bacterial flora
    Kenneth D R Setchell
    Division of Pathology, Clinical Mass Spectrometry, Cincinnati Children s Hospital Medical Center, and the Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati 45229, OH, USA
    Am J Clin Nutr 81:1072-9. 2005
    ..Equol, unlike the soy isoflavones daidzein or genistein, has a chiral center and therefore can occur as 2 distinct diastereoisomers...
  3. ncbi Comparing the pharmacokinetics of daidzein and genistein with the use of 13C-labeled tracers in premenopausal women
    Kenneth D R Setchell
    Clinical Mass Spectrometry, Children's Hospital Medical Center, Cincinnati, OH, USA
    Am J Clin Nutr 77:411-9. 2003
    ..The bioavailability of both isoflavones was nonlinear at higher intakes, suggesting that uptake is rate-limiting and saturable...
  4. ncbi Soy isoflavone phase II metabolism differs between rodents and humans: implications for the effect on breast cancer risk
    Kenneth D R Setchell
    Division of Pathology and Laboratory Medicine, Cincinnati Children s Hospital Medical Center, OH 45229, USA
    Am J Clin Nutr 94:1284-94. 2011
    ..Human and animal studies have produced conflicting results with regard to the effect of soy isoflavones on breast cancer risk. This may be due to differences in isoflavone metabolism...
  5. ncbi The pharmacokinetic behavior of the soy isoflavone metabolite S-(-)equol and its diastereoisomer R-(+)equol in healthy adults determined by using stable-isotope-labeled tracers
    Kenneth Dr Setchell
    Division of Pathology and Laboratory Medicine, Cincinnati Children s Hospital Medical Center, Cincinnati, OH 45229, USA
    Am J Clin Nutr 90:1029-37. 2009
    ..Little is known about the pharmacokinetics of the diastereoisomers, despite current interest in developing equol as a nutraceutical or pharmaceutical agent...
  6. ncbi The chemopreventive action of equol enantiomers in a chemically induced animal model of breast cancer
    Nadine M Brown
    Division of Pathology and Laboratory Medicine, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio, OH 45229, USA
    Carcinogenesis 31:886-93. 2010
    ..In conclusion, the novel finding that the unnatural enantiomer, R-(+)equol, was potently chemopreventive warrants investigation of its potential for breast cancer prevention and treatment...
  7. ncbi Pharmacokinetics of a slow-release formulation of soybean isoflavones in healthy postmenopausal women
    Kenneth D R Setchell
    Division of Pathology, Department of Pediatrics, Cincinnati Children s Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA
    J Agric Food Chem 53:1938-44. 2005
    ..These findings show that it is feasible to employ polymer matrices that slow the aqueous dissolution for preparing sustained-release formulations of soy isoflavones. Further studies to optimize such formulations are warranted...
  8. ncbi The clinical importance of the metabolite equol-a clue to the effectiveness of soy and its isoflavones
    Kenneth D R Setchell
    Clinical Mass Spectrometry, Department of Pediatrics, Cincinnati Children s Hospital Medical Center, OH 45229, USA
    J Nutr 132:3577-84. 2002
    ..The failure to distinguish those subjects who are "equol-producers" from "nonequol producers" in previous clinical studies could plausibly explain the variance in reported data on the health benefits of soy...
  9. ncbi Evidence for lack of absorption of soy isoflavone glycosides in humans, supporting the crucial role of intestinal metabolism for bioavailability
    Kenneth D R Setchell
    Division of Clinical Mass Spectrometry, Department of Pediatrics, Children s Hospital Medical Center, Cincinnati, OH 45229, USA
    Am J Clin Nutr 76:447-53. 2002
    ....